FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Viruses / Lessons in AIDS vaccine development learned from studies of ...
Viruses2013; 5(12); 2963-2976; doi: 10.3390/v5122963

Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.

Abstract: Equine infectious anemia (EIA), identified in 1843 [1] as an infectious disease of horses and as a viral infection in 1904, remains a concern in veterinary medicine today. Equine infectious anemia virus (EIAV) has served as an animal model of HIV-1/AIDS research since the original identification of HIV. Similar to other lentiviruses, EIAV has a high propensity for genomic sequence and antigenic variation, principally in its envelope (Env) proteins. However, EIAV possesses a unique and dynamic disease presentation that has facilitated comprehensive analyses of the interactions between the evolving virus population, progressive host immune responses, and the definition of viral and host correlates of immune control and vaccine efficacy. Summarized here are key findings in EIAV that have provided important lessons toward understanding long term immune control of lentivirus infections and the parameters for development of an enduring broadly protective AIDS vaccine.
Get Full Text
Publication Date: 2013-12-02 PubMed ID: 24316675PubMed Central: PMC3967156DOI: 10.3390/v5122963Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research emphasizes the instrumental role of the Equine Infectious Anemia Virus (EIAV) in understanding the development of an AIDS vaccine due to its comparable properties and unique progression. The study provides crucial explanations on the long-term immune control of lentivirus, setting parameters for the creation of a long-lasting, broad-spectrum AIDS vaccine.

Understanding EIAV

  • Equine Infectious Anemia (EIA) is a viral infection diagnosed in horses back in 1843 and confirmed as a virus in 1904. Despite advancements in veterinary medicine, this infectious disease still poses significant challenges.
  • The EIA virus has been utilized as a model for studying HIV-1/AIDS ever since HIV was first identified.
  • Like other lentiviruses, EIAV is characterized by significant genomic sequence variation, primarily in its envelope proteins. These variations are a key feature of many viruses, including HIV, and play a critical role in how the virus interacts with the host’s immune system and in the development of vaccines.

Role of EIAV in AIDS Vaccine Research

  • The unique and active disease presentation of the EIAV has allowed extensive examination of how the evolving virus population interacts with the progressing host immune responses.
  • This interaction and the distinctive progression of the disease have facilitated a comprehensive definition of viral and host correlates of immune control and vaccine efficacy.
  • Such valuable insights derived from EIAV could be instrumental in establishing an effective AIDS vaccine, highlighting the importance of this research.

Key Findings and Implications for AIDS Vaccine

  • The article summarizes vital discoveries regarding EIAV which have provided meaningful insights to better understand the long-term immune control of lentivirus infections. These infections, like HIV, are characterized by a slow progression, with an individual’s immune system playing a crucial role in controlling the disease.
  • These lessons drawn from EIAV research lay down potential guidelines for the development of an enduring and broadly protective AIDS vaccine. A comprehensive understanding of how similar lentiviruses behave and evolve can significantly enhance the potential to create an effective vaccine against AIDS.

Cite This Article

APA
Craigo JK, Montelaro RC. (2013). Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity. Viruses, 5(12), 2963-2976. https://doi.org/10.3390/v5122963

Publication

Viruses
ISSN: 1999-4915
NlmUniqueID: 101509722
Country: Switzerland
Language: English
Volume: 5
Issue: 12
Pages: 2963-2976

Researcher Affiliations

Craigo, Jodi K
  • Center for Vaccine Research, Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15261, USA. rmont@pitt.edu.
Montelaro, Ronald C

    MeSH Terms

    • AIDS Vaccines / immunology
    • AIDS Vaccines / isolation & purification
    • Animals
    • Antigenic Variation
    • Drug Discovery / trends
    • Equine Infectious Anemia / immunology
    • Equine Infectious Anemia / prevention & control
    • Genetic Variation
    • Horses
    • Humans
    • Infectious Anemia Virus, Equine / genetics
    • Infectious Anemia Virus, Equine / immunology

    Grant Funding

    • R01 AI025850 / NIAID NIH HHS
    • R01 AI25850 / NIAID NIH HHS

    References

    This article includes 59 references
    1. Lignée M. Mémoire et observations sur une maladie de sang, connue sous le nom d’anhémie hydrohémie, cachexie acquise du cheval. Rec. Med. Vet. Ec Alfort 1843;20:30–45.
    2. Craigo JK, Montelaro RC. Equine Infectious Anemia Virus (Retroviridae). Encyclopedia of Virology 3rd ed. Volume 3. Elsevier; Oxford, UK: 2008. pp. 167–174.
    3. Montelaro RC, Ball JM, Rushlow K. Equine Retroviruses. The Retroviridae Volume 2. Plenum Press; New York, NY, USA: 1993. pp. 257–360.
    4. Clements JE, Zink MC, Narayan O, Gabuzda DH. Lentivirus infection of macrophages.. Immunol Ser 1994;60:589-600.
      pubmed: 8251596
    5. Oaks JL, McGuire TC, Ulibarri C, Crawford TB. Equine infectious anemia virus is found in tissue macrophages during subclinical infection.. J Virol 1998 Sep;72(9):7263-9.
      pmc: PMC109949pubmed: 9696821doi: 10.1128/jvi.72.9.7263-7269.1998google scholar: lookup
    6. Harrold SM, Cook SJ, Cook RF, Rushlow KE, Issel CJ, Montelaro RC. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids.. J Virol 2000 Apr;74(7):3112-21.
      doi: 10.1128/JVI.74.7.3112-3121.2000pmc: PMC111810pubmed: 10708426google scholar: lookup
    7. Hammond SA, Li F, McKeon BM Sr, Cook SJ, Issel CJ, Montelaro RC. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.. J Virol 2000 Jul;74(13):5968-81.
      doi: 10.1128/JVI.74.13.5968-5981.2000pmc: PMC112093pubmed: 10846078google scholar: lookup
    8. Kono Y, Hirasawa K, Fukunaga Y, Taniguchi T. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs.. Natl Inst Anim Health Q (Tokyo) 1976 Spring;16(1):8-15.
      pubmed: 177894
    9. Craigo JK, Leroux C, Howe L, Steckbeck JD, Cook SJ, Issel CJ, Montelaro RC. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication.. J Gen Virol 2002 Jun;83(Pt 6):1353-1359.
      pubmed: 12029150doi: 10.1099/0022-1317-83-6-1353google scholar: lookup
    10. Pandrea I, Onanga R, Kornfeld C, Rouquet P, Bourry O, Clifford S, Telfer PT, Abernethy K, White LT, Ngari P, Müller-Trutwin M, Roques P, Marx PA, Simon F, Apetrei C. High levels of SIVmnd-1 replication in chronically infected Mandrillus sphinx.. Virology 2003 Dec 5;317(1):119-27.
      doi: 10.1016/j.virol.2003.08.015pubmed: 14675630google scholar: lookup
    11. Pandrea I, Onanga R, Souquiere S, Mouinga-Ondéme A, Bourry O, Makuwa M, Rouquet P, Silvestri G, Simon F, Roques P, Apetrei C. Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding.. J Virol 2008 Jun;82(11):5501-9.
      doi: 10.1128/JVI.02555-07pmc: PMC2395173pubmed: 18385229google scholar: lookup
    12. VandeWoude S, Apetrei C. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.. Clin Microbiol Rev 2006 Oct;19(4):728-62.
      doi: 10.1128/CMR.00009-06pmc: PMC1592692pubmed: 17041142google scholar: lookup
    13. Leroux C, Issel CJ, Montelaro RC. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.. J Virol 1997 Dec;71(12):9627-39.
      pmc: PMC230271pubmed: 9371627doi: 10.1128/jvi.71.12.9627-9639.1997google scholar: lookup
    14. Leroux C, Craigo JK, Issel CJ, Montelaro RC. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.. J Virol 2001 May;75(10):4570-83.
      doi: 10.1128/JVI.75.10.4570-4583.2001pmc: PMC114210pubmed: 11312327google scholar: lookup
    15. Lichtenstein DL, Issel CJ, Montelaro RC. Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus.. J Virol 1996 Jun;70(6):3346-54.
      pmc: PMC190205pubmed: 8648664doi: 10.1128/jvi.70.6.3346-3354.1996google scholar: lookup
    16. Sponseller BA, Sparks WO, Wannemuehler Y, Li Y, Antons AK, Oaks JL, Carpenter S. Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease.. Virology 2007 Jun 20;363(1):156-65.
      doi: 10.1016/j.virol.2007.01.037pubmed: 17328936google scholar: lookup
    17. Zheng YH, Nakaya T, Sentsui H, Kameoka M, Kishi M, Hagiwara K, Takahashi H, Kono Y, Ikuta K. Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse.. J Gen Virol 1997 Apr;78 ( Pt 4):807-20.
      pubmed: 9129653doi: 10.1099/0022-1317-78-4-807google scholar: lookup
    18. Zheng YH, Sentsui H, Nakaya T, Kono Y, Ikuta K. In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domain.. J Virol 1997 Jul;71(7):5031-9.
      pmc: PMC191736pubmed: 9188568doi: 10.1128/jvi.71.7.5031-5039.1997google scholar: lookup
    19. Zheng YH, Sentsui H, Kono Y, Ikuta K. Mutations occurring during serial passage of Japanese equine infectious anemia virus in primary horse macrophages.. Virus Res 2000 Jun;68(1):93-8.
      doi: 10.1016/S0168-1702(00)00147-7pubmed: 10930666google scholar: lookup
    20. Craigo JK, Sturgeon TJ, Cook SJ, Issel CJ, Leroux C, Montelaro RC. Apparent elimination of EIAV ancestral species in a long-term inapparent carrier.. Virology 2006 Jan 20;344(2):340-53.
      doi: 10.1016/j.virol.2005.09.006pubmed: 16226288google scholar: lookup
    21. Greene WK, Meers J, del Fierro G, Carnegie PR, Robinson WF. Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats.. Arch Virol 1993;133(1-2):51-62.
      doi: 10.1007/BF01309743pubmed: 8240017google scholar: lookup
    22. Leroux C, Chastang J, Greenland T, Mornex JF. Genomic heterogeneity of small ruminant lentiviruses: existence of heterogeneous populations in sheep and of the same lentiviral genotypes in sheep and goats.. Arch Virol 1997;142(6):1125-37.
      doi: 10.1007/s007050050147pubmed: 9229003google scholar: lookup
    23. Simmonds P, Balfe P, Ludlam CA, Bishop JO, Brown AJ. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.. J Virol 1990 Dec;64(12):5840-50.
      pmc: PMC248744pubmed: 2243378doi: 10.1128/jvi.64.12.5840-5850.1990google scholar: lookup
    24. Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.. Cell 1986 Jun 6;45(5):637-48.
      doi: 10.1016/0092-8674(86)90778-6pubmed: 2423250google scholar: lookup
    25. Suarez DL, Whetstone CA. Identification of hypervariable and conserved regions in the surface envelope gene in the bovine lentivirus.. Virology 1995 Oct 1;212(2):728-33.
      doi: 10.1006/viro.1995.1532pubmed: 7571444google scholar: lookup
    26. Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC. Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.. Vaccine 2010 Nov 29;28(51):8095-104.
      doi: 10.1016/j.vaccine.2010.10.003pmc: PMC2997116pubmed: 20955830google scholar: lookup
    27. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection.. Annu Rev Med 2002;53:557-93.
      doi: 10.1146/annurev.med.53.082901.104024pubmed: 11818490google scholar: lookup
    28. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.. Nature 1997 May 8;387(6629):183-8.
      doi: 10.1038/387183a0pubmed: 9144289google scholar: lookup
    29. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.. Nat Med 1999 May;5(5):512-7.
      doi: 10.1038/8394pubmed: 10229227google scholar: lookup
    30. Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers.. J Virol 2003 Feb;77(3):1659-65.
      doi: 10.1128/JVI.77.3.1659-1665.2003pmc: PMC140995pubmed: 12525599google scholar: lookup
    31. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, Pierson TC, Margolick JB, Siliciano RF, Siliciano JD. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.. J Virol 2004 Jun;78(12):6122-33.
      doi: 10.1128/JVI.78.12.6122-6133.2004pmc: PMC416493pubmed: 15163705google scholar: lookup
    32. Lassen KG, Bailey JR, Siliciano RF. Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo.. J Virol 2004 Sep;78(17):9105-14.
      doi: 10.1128/JVI.78.17.9105-9114.2004pmc: PMC506937pubmed: 15308706google scholar: lookup
    33. Issel CJ, Adams WV Jr, Meek L, Ochoa R. Transmission of equine infectious anemia virus from horses without clinical signs of disease.. J Am Vet Med Assoc 1982 Feb 1;180(3):272-5.
      pubmed: 6276353
    34. McGuire TC, Tumas DB, Byrne KM, Hines MT, Leib SR, Brassfield AL, O'Rourke KI, Perryman LE. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.. J Virol 1994 Mar;68(3):1459-67.
      pmc: PMC236601pubmed: 8107209doi: 10.1128/jvi.68.3.1459-1467.1994google scholar: lookup
    35. O'Rourke K, Perryman LE, McGuire TC. Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.. J Gen Virol 1988 Mar;69 ( Pt 3):667-74.
      doi: 10.1099/0022-1317-69-3-667pubmed: 3351480google scholar: lookup
    36. Rwambo PM, Issel CJ, Adams WV Jr, Hussain KA, Miller M, Montelaro RC. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.. Arch Virol 1990;111(3-4):199-212.
      doi: 10.1007/BF01311054pubmed: 2162160google scholar: lookup
    37. Montelaro RC, Ball JM, Issel CJ. Characterization of EIAV immunogenicity during persistent infections: humoral responses and antigen targets.. Dev Biol Stand 1990;72:19-30.
      pubmed: 1704323
    38. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.. J Virol 1997 May;71(5):3840-52.
      pmc: PMC191535pubmed: 9094660doi: 10.1128/jvi.71.5.3840-3852.1997google scholar: lookup
    39. Montelaro RC, Cole KS, Hammond SA. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development.. AIDS Res Hum Retroviruses 1998 Oct;14 Suppl 3:S255-9.
      doi: 10.1089/aid.1998.14.255pubmed: 9814952google scholar: lookup
    40. Hussain KA, Issel CJ, Schnorr KL, Rwambo PM, West M, Montelaro RC. Antigenic mapping of the envelope proteins of equine infectious anemia virus: identification of a neutralization domain and a conserved region on glycoprotein 90.. Arch Virol 1988;98(3-4):213-24.
      doi: 10.1007/BF01322170pubmed: 2450529google scholar: lookup
    41. Payne SL, Fang FD, Liu CP, Dhruva BR, Rwambo P, Issel CJ, Montelaro RC. Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV.. Virology 1987 Dec;161(2):321-31.
      doi: 10.1016/0042-6822(87)90124-3pubmed: 2825406google scholar: lookup
    42. Payne SL, Salinovich O, Nauman SM, Issel CJ, Montelaro RC. Course and extent of variation of equine infectious anemia virus during parallel persistent infections.. J Virol 1987 Apr;61(4):1266-70.
      pmc: PMC254092pubmed: 3029423doi: 10.1128/jvi.61.4.1266-1270.1987google scholar: lookup
    43. Payne SL, Rushlow K, Dhruva BR, Issel CJ, Montelaro RC. Localization of conserved and variable antigenic domains of equine infectious anemia virus envelope glycoproteins using recombinant env-encoded protein fragments produced in Escherichia coli.. Virology 1989 Oct;172(2):609-15.
      doi: 10.1016/0042-6822(89)90203-1pubmed: 2552661google scholar: lookup
    44. Perryman LE, O'Rourke KI, McGuire TC. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.. J Virol 1988 Aug;62(8):3073-6.
      pmc: PMC253753pubmed: 2839723doi: 10.1128/jvi.62.8.3073-3076.1988google scholar: lookup
    45. Howe L, Leroux C, Issel CJ, Montelaro RC. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.. J Virol 2002 Nov;76(21):10588-97.
      doi: 10.1128/JVI.76.21.10588-10597.2002pmc: PMC136617pubmed: 12368301google scholar: lookup
    46. Howe L, Craigo JK, Issel CJ, Montelaro RC. Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain.. J Gen Virol 2005 Jan;86(Pt 1):139-149.
      doi: 10.1099/vir.0.80374-0pubmed: 15604441google scholar: lookup
    47. Tagmyer TL, Craigo JK, Cook SJ, Issel CJ, Montelaro RC. Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus.. J Gen Virol 2007 Apr;88(Pt 4):1324-1336.
      doi: 10.1099/vir.0.82391-0pubmed: 17374779google scholar: lookup
    48. Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, Montelaro RC. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.. J Virol 2008 Apr;82(8):4052-63.
      doi: 10.1128/JVI.02028-07pmc: PMC2292999pubmed: 18234792google scholar: lookup
    49. Issel CJ, Horohov DW, Lea DF, Adams WV Jr, Hagius SD, McManus JM, Allison AC, Montelaro RC. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.. J Virol 1992 Jun;66(6):3398-408.
      pmc: PMC241120pubmed: 1316455doi: 10.1128/jvi.66.6.3398-3408.1992google scholar: lookup
    50. Wang SZ, Rushlow KE, Issel CJ, Cook RF, Cook SJ, Raabe ML, Chong YH, Costa L, Montelaro RC. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein.. Virology 1994 Feb 15;199(1):247-51.
      doi: 10.1006/viro.1994.1120pubmed: 8116252google scholar: lookup
    51. Grund CH, Lechman ER, Pezzuolo NA, Issel CJ, Montelaro RC. Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies.. J Gen Virol 1996 Mar;77 ( Pt 3):435-42.
      doi: 10.1099/0022-1317-77-3-435pubmed: 8601778google scholar: lookup
    52. Raabe ML, Issel CJ, Cook SJ, Cook RF, Woodson B, Montelaro RC. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement.. Virology 1998 May 25;245(1):151-62.
      doi: 10.1006/viro.1998.9142pubmed: 9614876google scholar: lookup
    53. Shen RX, Wang Z. EIAV: A National Review of Policies, Programs, and Future Objectives. American Quarter Horse Association Amarillo, TX, USA: 1985. Development and Use of an Equine Infectious Anemia Donkey Leucocyte Attenuated Vaccine; pp. 135–148.
    54. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, Issel CJ, Montelaro RC. Envelope variation as a primary determinant of lentiviral vaccine efficacy.. Proc Natl Acad Sci U S A 2007 Sep 18;104(38):15105-10.
      pmc: PMC1986620pubmed: 17846425doi: 10.1073/pnas.0706449104google scholar: lookup
    55. Cook RF, Cook SJ, Bolin PS, Howe LJ, Zhou W, Montelaro RC, Issel CJ. Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies.. Vet Microbiol 2005 Jun 15;108(1-2):23-37.
      doi: 10.1016/j.vetmic.2005.04.004pubmed: 15885929google scholar: lookup
    56. Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, Issel CJ, Montelaro RC. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.. Vaccine 2007 Jan 15;25(5):834-45.
      doi: 10.1016/j.vaccine.2006.09.040pmc: PMC1855206pubmed: 17023099google scholar: lookup
    57. Hammond SA, Cook SJ, Falo LD Jr, Issel CJ, Montelaro RC. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus.. Virology 1999 Feb 1;254(1):37-49.
      doi: 10.1006/viro.1998.9550pubmed: 9927572google scholar: lookup
    58. Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.. J Virol 2003 Jul;77(13):7244-53.
      doi: 10.1128/JVI.77.13.7244-7253.2003pmc: PMC164776pubmed: 12805423google scholar: lookup
    59. Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, Issel C, Montelaro RC. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.. J Virol 2005 Mar;79(5):2666-77.
      doi: 10.1128/JVI.79.5.2666-2677.2005pmc: PMC548432pubmed: 15708986google scholar: lookup

    Citations

    This article has been cited 19 times.
    1. Wang XF, Zhang X, Ma W, Li J, Wang X. Host cell restriction factors of equine infectious anemia virus. Virol Sin 2023 Aug;38(4):485-496.
      doi: 10.1016/j.virs.2023.07.001pubmed: 37419416google scholar: lookup
    2. Hull-Nye D, Meadows T, Smith SR, Schwartz EJ. Key Factors and Parameter Ranges for Immune Control of Equine Infectious Anemia Virus Infection. Viruses 2023 Mar 6;15(3).
      doi: 10.3390/v15030691pubmed: 36992401google scholar: lookup
    3. Zhang X, Li J, Zhang M, Bai B, Ma W, Lin Y, Guo X, Wang XF, Wang X. A Novel, Fully Spliced, Accessory Gene in Equine Lentivirus with Distinct Rev-Responsive Element. J Virol 2022 Sep 28;96(18):e0098622.
      doi: 10.1128/jvi.00986-22pubmed: 36069548google scholar: lookup
    4. Resende CF, Santos AM, Cook RF, Victor RM, Câmara RJF, Gonçalves GP, Lima JG, Maciel E Silva AG, Leite RC, Dos Reis JKP. Low transmission rates of Equine infectious anemia virus (EIAV) in foals born to seropositive feral mares inhabiting the Amazon delta region despite climatic conditions supporting high insect vector populations. BMC Vet Res 2022 Jul 22;18(1):286.
      doi: 10.1186/s12917-022-03384-4pubmed: 35869474google scholar: lookup
    5. Knox A, Beddoe T. Isothermal Nucleic Acid Amplification Technologies for the Detection of Equine Viral Pathogens. Animals (Basel) 2021 Jul 20;11(7).
      doi: 10.3390/ani11072150pubmed: 34359278google scholar: lookup
    6. Wang XF, Bai B, Lin Y, Qi T, Du C, Song M, Wang X. High-Efficiency Rescue of Equine Infectious Anemia Virus from a CMV-Driven Infectious Clone. Virol Sin 2019 Dec;34(6):725-728.
      doi: 10.1007/s12250-019-00153-wpubmed: 31376080google scholar: lookup
    7. Ishak J, Unsunnidhal L, Martien R, Kusumawati A. In Vitro Evaluation of Chitosan-DNA Plasmid Complex Encoding Jembrana Disease Virus Env-TM Protein as a Vaccine Candidate. J Vet Res 2019 Mar;63(1):7-16.
      doi: 10.2478/jvetres-2019-0018pubmed: 30989130google scholar: lookup
    8. de Pablo-Maiso L, Doménech A, Echeverría I, Gómez-Arrebola C, de Andrés D, Rosati S, Gómez-Lucia E, Reina R. Prospects in Innate Immune Responses as Potential Control Strategies against Non-Primate Lentiviruses. Viruses 2018 Aug 17;10(8).
      doi: 10.3390/v10080435pubmed: 30126090google scholar: lookup
    9. Wang XF, Liu Q, Wang YH, Wang S, Chen J, Lin YZ, Ma J, Zhou JH, Wang X. Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies In Vitro and In Vivo. J Virol 2018 Apr 15;92(8).
      doi: 10.1128/JVI.02150-17pubmed: 29386282google scholar: lookup
    10. Brocca-Cofano E, Kuhrt D, Siewe B, Xu C, Haret-Richter GS, Craigo J, Labranche C, Montefiori DC, Landay A, Apetrei C, Pandrea I. Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction. J Virol 2017 Dec 1;91(23).
      doi: 10.1128/JVI.01051-17pubmed: 28931679google scholar: lookup
    11. Shivatare SS, Chang SH, Tsai TI, Tseng SY, Shivatare VS, Lin YS, Cheng YY, Ren CT, Lee CC, Pawar S, Tsai CS, Shih HW, Zeng YF, Liang CH, Kwong PD, Burton DR, Wu CY, Wong CH. Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies. Nat Chem 2016 Apr;8(4):338-46.
      doi: 10.1038/nchem.2463pubmed: 27001729google scholar: lookup
    12. Wang XF, Lin YZ, Li Q, Liu Q, Zhao WW, Du C, Chen J, Wang X, Zhou JH. Genetic Evolution during the development of an attenuated EIAV vaccine. Retrovirology 2016 Feb 3;13:9.
      doi: 10.1186/s12977-016-0240-6pubmed: 26842878google scholar: lookup
    13. Liu Q, Wang XF, Ma J, He XJ, Wang XJ, Zhou JH. Characterization of Equine Infectious Anemia Virus Integration in the Horse Genome. Viruses 2015 Jun 19;7(6):3241-60.
      doi: 10.3390/v7062769pubmed: 26102582google scholar: lookup
    14. Schwartz EJ, Nanda S, Mealey RH. Antibody escape kinetics of equine infectious anemia virus infection of horses. J Virol 2015 Jul;89(13):6945-51.
      doi: 10.1128/JVI.00137-15pubmed: 25878104google scholar: lookup
    15. Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC. Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine. PLoS Pathog 2015 Jan;11(1):e1004610.
      doi: 10.1371/journal.ppat.1004610pubmed: 25569288google scholar: lookup
    16. Du J, Wang X, Ma J, Wang J, Qin Y, Zhu C, Liu F, Shao Y, Zhou J, Qiao W, Liu X. Structural and biochemical insights into the V/I505T mutation found in the EIAV gp45 vaccine strain. Retrovirology 2014 Mar 21;11:26.
      doi: 10.1186/1742-4690-11-26pubmed: 24656154google scholar: lookup
    17. Liang H, Zhou B, Hu Z, Chu X, Wang X, Du C, Wang X. Development of a Broad-Spectrum Antigen-Capture ELISA Using Combined Anti-p26 Polyclonal and Monoclonal Antibodies for Detection of Equine Infectious Anemia Virus. Microorganisms 2025 Jun 27;13(7).
      doi: 10.3390/microorganisms13071500pubmed: 40732013google scholar: lookup
    18. Bai B, Zhang X, Zhang M, Ma W, Li J, Zhang H, Na L, Guo X, Lin Y, Wang XF, Wang X. EIAV encodes an accessory protein that antagonizes the host restriction factor equine tetherin. Proc Natl Acad Sci U S A 2025 Jul;122(26):e2413703122.
      doi: 10.1073/pnas.2413703122pubmed: 40549908google scholar: lookup
    19. Stelder JJ, Mihalca AD, Olesen AS, Kjær LJ, Boklund AE, Rasmussen TB, Marinov M, Alexe V, Balmoş OM, Bødker R. Potential mosquito vector attraction to- and feeding preferences for pigs in Romanian backyard farms. Front Vet Sci 2022;9:1046263.
      doi: 10.3389/fvets.2022.1046263pubmed: 36686172google scholar: lookup
    Subscribe to our newsletter
    Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.